Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Endometrial Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory or recurrent endometrial cancer.

Key facts

Study ID

NCT00003821

Run by

Genzyme, a Sanofi Company

People needed

0

Starts

1998-01-01

Last updated by the study team

2018-09-18

Who can join

Age: any, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Division of Gynecologic Oncology — St Louis, Missouri, United States
• East Carolina University School of Medicine — Greenville, North Carolina, United States
• Gynecologic Oncologists of NE Ohio — Akron, Ohio, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States
• Texas Oncology, P.A. — Dallas, Texas, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.